在结肠癌中辅助化疗:简单更好...更少是更多
Prasad Narayanan1, Shyam Aggarwal2, Manish Singhal3
1Department of Medical Oncology, Cytecare Hospital, Bengaluru, Karnataka, India.
South Asian journal of cancer
|March 10, 2025
概括
辅助治疗改善了结直肠癌 (CRC) 患者的治疗结果. 像CAPOX和SOX这样的更短的疗程提供了标准FOLFOX的替代方案,个性化的选择提高了治疗效率.
科学领域:
- 在瘤学瘤学.
- 医学瘤学 医学瘤学
- 胃肠病学 胃肠病学
背景情况:
- 辅助疗法显著有利于结直肠癌 (CRC) 的患者.
- 目前的标准治疗包括6个月的FOLFOX治疗,但如CAPOX和SOX等更短的治疗方案正在出现.
- 诸如SCOT,TOSCA,Alliance/SWOG80702,IDEA,ACHIEVE和HORG等临床试验正在评估这些治疗方法.
研究的目的:
- 审查目前对结直肠癌的辅助疗法选择.
- 讨论患者偏好和新生物标志物在治疗选择中的作用.
- 为了突出对老年CRC患者的考虑.
主要方法:
- 关键临床试验的综述,比较CRC的辅助化疗方案.
- 分析影响治疗决策的因素,包括患者偏好和分子标记.
- 考虑在治疗CRC的老年患者方面面临的具体挑战.
主要成果:
- 较短的辅助化疗方案 (CAPOX,SOX) 是标准FOLFOX的可行的替代方案.
- 使用分子生物标志物和循环瘤DNA (ctDNA) 优化患者选择,以进行最小残留疾病 (MRD) 监测.
- 老年患者由于并发病,多药和移动性问题需要特别注意.
结论:
- 优化结直肠癌的辅助疗法包括平衡疗效与患者特定因素.
- 个性化治疗选择,包括生物标志物和患者偏好,对于改善治疗结果至关重要.
- 针对性管理策略对于接受CRC治疗的老年人群至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs for Treatment of Diarrhea-Predominant IBS
134
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
134


